Heparanase induces tissue factor expression in vascular endothelial and cancer cells

Summary.  Background: Over‐expression of tissue factor (TF) and activation of the coagulation system are common in cancer patients. Heparanase is an endo‐β‐d‐glucuronidase that cleaves heparan sulfate chains on cell surfaces and in the extracellular matrix, activity that closely correlates with cell invasion, angiogenesis and tumor metastasis. The study was undertaken to investigate the involvement of heparanase in TF expression. Methods: Tumor‐derived cell lines were transfected with heparanase cDNA and TF expression was examined. The effect of exogenous addition of active and inactive heparanase on TF expression and activity was studied in tumor cell lines and primary human umbilical vein endothelial cells. TF expression was also explored in heparanase over‐expressing transgenic (Tg) mice. Blast cells were collected from acute leukemia patients and TF and heparanase expression levels were analyzed. Results: Over‐expression of heparanase in tumor‐derived cell lines resulted in a 2‐fold increase in TF expression levels, and a similar trend was observed in heparanase Tg mice in vivo. Likewise, exogenous addition of heparanase to endothelial or tumor‐derived cells resulted in enhanced TF expression and activity. Interestingly, TF expression was also induced in response to enzymatically inactive heparanase, suggesting that this effect was independent of heparanase enzymatic activity. The regulatory effect of heparanase on TF expression involved activation of the p38 signaling pathway. A positive correlation between TF expression levels and heparanase activity was found in blasts collected from 22 acute leukemia patients. Conclusions: Our results indicate that in addition to its well‐known function as an enzyme paving a way for invading cells, heparanase also participates in the regulation of TF gene expression and its related coagulation pathways.

[1]  F. Nakhoul,et al.  An ELISA method for the detection and quantification of human heparanase. , 2006, Biochemical and biophysical research communications.

[2]  H. Versteeg,et al.  Emerging insights in tissue factor-dependent signaling events. , 2006, Seminars in thrombosis and hemostasis.

[3]  I. Vlodavsky,et al.  Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. , 2006, Cancer research.

[4]  N. Barbarroja,et al.  Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. , 2006, Arthritis and rheumatism.

[5]  Zhe Zhang,et al.  Cellular Uptake of Mammalian Heparanase Precursor Involves Low Density Lipoprotein Receptor-related Proteins, Mannose 6-Phosphate Receptors, and Heparan Sulfate Proteoglycans* , 2005, Journal of Biological Chemistry.

[6]  R. Mrak,et al.  Heparanase, TrkC and p75NTR: their functional involvement in human medulloblastoma cell invasion. , 2005, International journal of oncology.

[7]  J. Meyerhardt,et al.  Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. , 2005, JAMA.

[8]  I. Vlodavsky,et al.  Identification and Characterization of Heparin/Heparan Sulfate Binding Domains of the Endoglycosidase Heparanase* , 2005, Journal of Biological Chemistry.

[9]  P. Gattuso,et al.  Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes. , 2005, Journal of the American College of Surgeons.

[10]  R. Sarid,et al.  Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  U. Pendurthi,et al.  Tissue factor-factor VIIa signaling. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[12]  Tomohiro Sato,et al.  Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis , 2004, Journal of surgical oncology.

[13]  S. Coughlin,et al.  Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. , 2004, Blood.

[14]  M. Flugelman,et al.  Heparanase Induces Endothelial Cell Migration via Protein Kinase B/Akt Activation* , 2004, Journal of Biological Chemistry.

[15]  R. Alon,et al.  Enzymatically Quiescent Heparanase Augments T Cell Interactions with VCAM-1 and Extracellular Matrix Components under Versatile Dynamic Contexts1 , 2004, The Journal of Immunology.

[16]  M. Flugelman,et al.  Processing and activation of latent heparanase occurs in lysosomes , 2004, Journal of Cell Science.

[17]  T. Weinstein,et al.  Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  C. Nardella,et al.  Mechanism of activation of human heparanase investigated by protein engineering. , 2004, Biochemistry.

[19]  M. De Cicco The prothrombotic state in cancer: pathogenic mechanisms. , 2004, Critical reviews in oncology/hematology.

[20]  F. Zhan,et al.  High heparanase activity in multiple myeloma is associated with elevated microvessel density. , 2003, Cancer research.

[21]  I. Vlodavsky,et al.  Heparanase affects adhesive and tumorigenic potential of human glioma cells. , 2003, Cancer research.

[22]  A. Hongo,et al.  Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  R. Heinrikson,et al.  Heterodimer formation is essential for heparanase enzymatic activity. , 2003, Biochemical and biophysical research communications.

[24]  Kenichi Tanaka,et al.  Heparanase Expression and Angiogenesis in Endometrial Cancer , 2003, Gynecologic and Obstetric Investigation.

[25]  B. Geiger,et al.  Heparanase mediates cell adhesion independent of its enzymatic activity , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  T. Fujiwara,et al.  Heparanase Expression Correlates with Invasion and Poor Prognosis in Gastric Cancers , 2003, Laboratory Investigation.

[27]  N. Nara,et al.  Induction of tissue factor expression in human monocytic cells by protease inhibitors through activating activator protein-1 (AP-1) with phosphorylation of Jun-N-terminal kinase and p38. , 2003, Thrombosis research.

[28]  P. Gattuso,et al.  Heparanase-1 expression is associated with the metastatic potential of breast cancer. , 2002, Surgery.

[29]  R. Abramovitch,et al.  Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Misako Sato,et al.  Heparanase: A Key Enzyme in Invasion and Metastasis of Gastric Carcinoma , 2002, Modern Pathology.

[31]  J. Mössner,et al.  Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma , 2002, British Journal of Cancer.

[32]  Motowo Nakajima,et al.  Expression of three extracellular matrix degradative enzymes in bladder cancer , 2001, International journal of cancer.

[33]  E. Mitrani,et al.  Expression Pattern and Secretion of Human and Chicken Heparanase Are Determined by Their Signal Peptide Sequence* , 2001, The Journal of Biological Chemistry.

[34]  I. Vlodavsky,et al.  Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. , 2001, The Journal of clinical investigation.

[35]  I. Pecker,et al.  The FASEB Journal express article 10.1096/fj.00-0895fje. Published online May 29, 2001. , 2022 .

[36]  H. Friess,et al.  Heparanase expression in primary and metastatic pancreatic cancer. , 2001, Cancer research.

[37]  N. Nagasue,et al.  The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  I. Vlodavsky Preparation of Extracellular Matrices Produced by Cultured Corneal Endothelial and PF‐HR9 Endodermal Cells , 1999, Current protocols in cell biology.

[39]  J. Gready,et al.  Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. , 2000, Biochemistry.

[40]  Thiennu H. Vu,et al.  Matrix metalloproteinases: effectors of development and normal physiology. , 2000, Genes & development.

[41]  C. Parish,et al.  Evidence that platelet and tumour heparanases are similar enzymes. , 1999, The Biochemical journal.

[42]  P. Nawroth,et al.  Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  I. Vlodavsky,et al.  Substrate Specificity of Heparanases from Human Hepatoma and Platelets* , 1998, The Journal of Biological Chemistry.

[44]  J. Platt,et al.  Regulation of platelet heparanase during inflammation: Role of pH and proteinases , 1998, Journal of cellular physiology.

[45]  C. Parish,et al.  Human platelet heparanase: purification, characterization and catalytic activity. , 1998, The Biochemical journal.

[46]  T. Luther,et al.  Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. , 1994, The Journal of clinical investigation.

[47]  I. Cohen,et al.  Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. , 1992, Invasion & metastasis.

[48]  J. Folkman,et al.  Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. , 1989, Biochemistry.

[49]  Z. Fuks,et al.  Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes. , 1985, The Journal of clinical investigation.

[50]  Z. Fuks,et al.  Degradation of sulfated proteoglycans in the subendothelial extracellular matrix by human platelet heparitinase. , 1984, The Journal of clinical investigation.

[51]  T. Irimura,et al.  Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. , 1984, The Journal of biological chemistry.

[52]  Z. Fuks,et al.  Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. , 1983, Cancer research.

[53]  T. Irimura,et al.  Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. , 1983, Science.